All Times EDT
Legend:
Activity Details
440 * !
Thu, 8/6/2020,
10:00 AM -
11:50 AM
Virtual
Let’s Make Everyone and Everything Count! Benefit-Risk Assessment Challenges, Lessons and Impacts in the Age of Big Data from Clinical Trials to Real-World Evidence — Topic Contributed Papers
Biopharmaceutical Section , ENAR, Royal Statistical Society
Organizer(s): Shahrul Mt-Isa, Merck
Chair(s): Shahrul Mt-Isa, Merck
10:05 AM
Individualized Treatment Choices and Benefit-Risk Prediction in Cardiovascular Clinical Trials
John Gregson ; Ruth Owen, LSHTM; Stuart Pocock, LSHTM; Shahrul Mt-Isa, Merck; Richard Baumgartner, Merck
10:25 AM
Do Birds of a Feather Flock Together? a Question of Credible Subgroup Identification and Inference on Benefitting Populations in Clinical Trials
Duy Ngo, Western Michigan University ; Patrick Schnell, The Ohio State University College of Public Health; Richard Baumgartner, Merck; Shahrul Mt-Isa, Merck; Jie Chen, Merck & Co., Inc.; Dai Feng, AbbVie
10:45 AM
Bayesian Bivariate Subgroup Analysis for Risk–benefit Evaluation
Nicholas C. Henderson, University of Michigan-Ann Arbor
11:05 AM
Opportunities and Challenges of Real-World Data (RWD) in Benefit-Risk Assessment (BRA)
Emilie Scherrer, Merck & Co Inc
11:25 AM
Everyone Counts - Regulating the Evidence from Clinical Trial Data to Real-World Evidence for the Public Good: The Past, Present, and Future
Lisa LaVange, UNC-CH
11:45 AM
Floor Discussion
